A Phase 3 interventional study of Durvalumab +Tremelimumab and Paclitaxel + carboplatin in Non Small Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 210 sites in 29 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, reaches primary completion later than 2 of the 36 other live ones, and was the 13th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 953 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 11th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 44 in phase 3, reaches primary completion later than 3 of the 77 other live ones, and was the 80th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
Patients will be randomized in a 1:1 to receive treatment with durvalumab + tremelimumab combination therapy or SoC therapy. The primary objective of this study is to assess the efficacy of combination treatment compared with SoC in terms of Overall Survival (OS) in patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in the study, patients should fulfill the following criteria:
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
Biological: Durvalumab +Tremelimumab
Standard of Care chemotherapy treatment
Drug: Paclitaxel + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + cisplatin · Drug: Pemetrexed + carboplatin
Drug pages: Durvalumab · Tremelimumab
Drug pages: Paclitaxel · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Cisplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Cisplatin
Chemotherapy Agent
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Carboplatin
Chemotherapy Agent
Also known as: Platinum based Standard of Care Chemotherapy
Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).
OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive. bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). bTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available. tTMB analysis sets are defined same as the bTMB analysis sets.
Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets
The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive. Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort.
Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). PD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: FAS included all randomized participants prior to end of global recruitment. China Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD. bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.
APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.
Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).
PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
Time frame: Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.
OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
Time frame: Months 12, 18 and 24
OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
Time frame: Months 12, 18 and 24
Serum Concentrations of Durvalumab
Blood samples were collected to determine the serum concentration of durvalumab.
Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3
Serum Concentrations of Tremelimumab
Blood samples were collected to determine the serum concentration of tremelimumab.
Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.
Number of Participants With ADA Response to Tremelimumab
Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
Time frame: At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.
A total of 192 centers across 29 countries in North America, Latin America, Asia, Europe and Gulf countries randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small-cell lung cancer (NSCLC) in this study. First participant was enrolled on 03 November 2015 and final data cut-off (DCO) date was 24 June 2019 for Global cohort and 21 September 2020 for China cohort. SoC = standard of care
| Milestone | All Participants: Durvalumab + Tremelimumab | All Participants: SoC Chemotherapy |
|---|---|---|
| Started | 474 | 479 |
| Randomized in global cohort | 410 | 413 |
| Received treatment in global cohort | 410 | 399 |
| Randomized in china cohort | 78 | 82 |
| Received treatment in china cohort | 77 | 78 |
| Included in both cohorts (global and china) | 14 | 16 |
| Ongoing in study at dco for final analysis in global cohort | 75 | 67 |
| Ongoing in study at dco for final analysis in china cohort | 27 | 18 |
| Completed | 99 | 83 |
| Not completed | 375 | 396 |
| Withdrew: Death | 367 | 377 |
| Withdrew: Withdrawal by subject | 8 | 19 |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set | 11.7 (8.6 to 15.2) | 9.1 (7.8 to 12.6) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| months | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|
| OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set | 15.0 (10.5 to 27.4) | 11.7 (8.6 to 20.5) |
OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive. bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). bTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available. tTMB analysis sets are defined same as the bTMB analysis sets.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥16 mut/Mb analysis set | 12.1 (8.6 to 15.0) | 11.9 (8.5 to 15.9) |
| bTMB ≥12 mut/Mb analysis set | 10.9 (8.6 to 12.6) | 10.3 (8.3 to 12.9) |
| PD-L1 negative analysis set | 11.1 (8.1 to 14.7) | 12.5 (9.9 to 16.2) |
| bTMB <20 mut/Mb analysis set | 9.9 (7.7 to 12.8) | 11.5 (8.8 to 13.7) |
| bTMB non-evaluable analysis set | 9.3 (7.2 to 15.5) | 10.4 (9.4 to 13.8) |
| tTMB ≥14 mut/Mb analysis set | 17.5 (9.8 to NA) | 10.6 (7.0 to 20.9) |
| tTMB ≥12 mut/Mb analysis set | 11.1 (7.0 to 17.5) | 13.9 (9.0 to 17.9) |
| tTMB ≥10 mut/Mb analysis set | 11.1 (7.2 to 15.7) | 10.6 (9.0 to 15.7) |
| tTMB ≥8 mut/Mb analysis set | 11.0 (7.8 to 15.7) | 10.2 (8.0 to 13.5) |
The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive. Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| FAS | 10.9 (9.3 to 12.6) | 12.1 (10.3 to 13.5) | 20.0 (15.0 to 28.7) | 14.1 (9.5 to 19.4) |
| PD-L1 TC ≥25% analysis set | 12.2 (9.7 to 15.2) | 10.4 (8.6 to 12.2) | 36.6 (15.5 to NA) | 15.8 (9.0 to 26.9) |
| PD-L1 TC ≥50% analysis set | 14.1 (10.0 to 19.3) | 10.5 (8.7 to 12.6) | 36.6 (16.9 to NA) | 15.8 (9.0 to 26.9) |
The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥20 mut/Mb analysis set | 4.2 (2.7 to 5.6) | 5.1 (4.2 to 5.6) |
| bTMB ≥16 mut/Mb analysis set | 4.2 (2.8 to 5.5) | 5.5 (4.4 to 5.8) |
| bTMB ≥12 mut/Mb analysis set | 3.9 (2.8 to 4.8) | 5.1 (4.4 to 5.6) |
| tTMB ≥14 mut/Mb analysis set | 8.7 (5.2 to 22.3) | 5.8 (4.4 to 7.9) |
| tTMB ≥12 mut/Mb analysis set | 5.2 (3.8 to 6.9) | 5.8 (4.2 to 6.6) |
| tTMB ≥10 mut/Mb analysis set | 4.3 (2.8 to 5.5) | 5.1 (4.2 to 5.8) |
| tTMB ≥8 mut/Mb analysis set | 4.4 (2.9 to 5.5) | 5.0 (4.2 to 5.6) |
PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). PD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: FAS included all randomized participants prior to end of global recruitment. China Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PD-L1-negative NSCLC analysis set | 4.1 (2.8 to 5.2) | 5.6 (4.6 to 6.0) | 5.1 (2.8 to 7.2) | 6.0 (4.0 to 7.5) |
| FAS | 4.0 (2.9 to 4.2) | 5.6 (5.3 to 5.7) | 4.2 (2.8 to 7.2) | 6.0 (5.5 to 7.5) |
| PD-L1 TC ≥25% analysis set | 4.2 (3.2 to 5.7) | 5.4 (4.4 to 5.6) | 6.8 (4.1 to 8.4) | 5.7 (4.2 to 8.5) |
| PD-L1 TC ≥50% analysis set | 4.6 (3.1 to 6.0) | 5.4 (4.3 to 5.6) | 6.8 (4.2 to 20.2) | 5.7 (4.2 to 8.5) |
The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD. bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay. tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥20 mut/Mb analysis set | 27.5 | 43.3 |
| bTMB ≥16 mut/Mb analysis set | 31.2 | 46.1 |
| bTMB ≥12 mut/Mb analysis set | 28.7 | 42.0 |
| tTMB ≥14 mut/Mb analysis set | 61.3 | 44.7 |
| tTMB ≥12 mut/Mb analysis set | 42.6 | 41.8 |
| tTMB ≥10 mut/Mb analysis set | 37.7 | 42.5 |
| tTMB ≥8 mut/Mb analysis set | 36.7 | 41.2 |
The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD. PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PD-L1-negative NSCLC analysis set | 23.1 | 38.8 | 23.1 | 41.4 |
| FAS | 25.9 | 41.7 | 35.9 | 39.0 |
| PD-L1 TC ≥25% analysis set | 35.2 | 43.9 | 54.8 | 40.6 |
| PD-L1 TC ≥50% analysis set | 37.4 | 44.0 | 60.0 | 46.4 |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥20 mut/Mb analysis set | 11.6 (6.7 to 21.5) | 4.2 (3.0 to 6.9) |
| bTMB ≥16 mut/Mb analysis set | 10.6 (4.2 to 21.5) | 4.3 (3.0 to 5.9) |
| bTMB ≥12 mut/Mb analysis set | 11.5 (6.7 to 18.8) | 4.3 (3.0 to 5.6) |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PD-L1-negative NSCLC analysis set | 10.2 (2.8 to 18.8) | 4.9 (4.2 to 6.1) | 10.5 (1.4 to NA) | 6.1 (3.0 to 11.7) |
| FAS | 11.1 (6.9 to 15.2) | 4.9 (4.2 to 5.6) | 12.9 (5.4 to 33.6) | 6.1 (4.4 to 7.2) |
The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥20 mut/Mb analysis set | 25.6 (15.7 to 36.6) | 7.0 (1.9 to 16.8) |
| bTMB ≥16 mut/Mb analysis set | 22.0 (14.1 to 31.1) | 12.3 (6.1 to 20.8) |
| bTMB ≥12 mut/Mb analysis set | 21.6 (15.2 to 28.9) | 13.8 (8.3 to 20.6) |
The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PD-L1-negative NSCLC analysis set | 18.2 (10.9 to 26.9) | 12.1 (6.3 to 19.9) | 15.6 (4.0 to 34.4) | 11.3 (2.3 to 28.5) |
| FAS | 20.2 (16.4 to 24.3) | 14.9 (11.4 to 18.9) | 23.9 (14.8 to 34.2) | 16.6 (8.5 to 27.0) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| bTMB ≥20 mut/Mb analysis set | 10.6 (8.5 to 14.4) | 8.6 (7.3 to 12.6) |
| bTMB ≥16 mut/Mb analysis set | 10.9 (8.5 to 14.1) | 10.5 (8.0 to 13.2) |
| bTMB ≥12 mut/Mb analysis set | 9.9 (8.2 to 11.7) | 9.0 (7.8 to 10.8) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
| months | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PD-L1-negative NSCLC analysis set | 9.1 (6.9 to 12.8) | 12.4 (8.8 to 14.9) | 13.8 (10.1 to 27.4) | 10.3 (6.5 to 14.1) |
| FAS | 9.4 (8.2 to 10.9) | 10.4 (9.1 to 11.5) | 15.5 (12.5 to 24.5) | 12.9 (9.2 to 15.4) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy |
|---|---|---|
| Month 12: bTMB ≥20 mut/Mb analysis set | 49.3 (37.1 to 60.4) | 40.8 (28.3 to 52.9) |
| Month 12: bTMB ≥16 mut/Mb analysis set | 50.5 (40.0 to 60.2) | 48.9 (38.2 to 58.8) |
| Month 12: bTMB ≥12 mut/Mb analysis set | 46.9 (38.5 to 54.8) | 44.6 (36.1 to 52.7) |
| Month 18: bTMB ≥20 mut/Mb analysis set | 36.2 (25.1 to 47.4) | 20.4 (11.3 to 31.4) |
| Month 18: bTMB ≥16 mut/Mb analysis set | 35.5 (25.9 to 45.1) | 28.5 (19.5 to 38.1) |
| Month 18: bTMB ≥12 mut/Mb analysis set | 29.4 (22.1 to 36.9) | 27.8 (20.6 to 35.4) |
| Month 24: bTMB ≥20 mut/Mb analysis set | 26.1 (16.4 to 36.8) | 13.6 (6.4 to 23.6) |
| Month 24: bTMB ≥16 mut/Mb analysis set | 24.0 (15.8 to 33.2) | 18.2 (11.0 to 26.9) |
| Month 24: bTMB ≥12 mut/Mb analysis set | 21.3 (15.0 to 28.4) | 19.0 (12.9 to 26.0) |
The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue). Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.
| percentage of participants | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| Month 12: PD-L1-negative NSCLC analysis set | 47.8 (37.2 to 57.6) | 52.8 (42.6 to 61.9) | 68.0 (46.1 to 82.5) | 46.4 (27.6 to 63.3) |
| Month 12: FAS | 47.7 (42.8 to 52.5) | 50.0 (45.0 to 54.8) | 72.8 (61.3 to 81.3) | 53.1 (41.7 to 63.2) |
| Month 18: PD-L1-negative NSCLC analysis set | 34.1 (24.5 to 43.9) | 34.5 (25.4 to 43.8) | 44.0 (24.5 to 61.9) | 39.3 (21.7 to 56.5) |
| Month 18: FAS | 34.8 (30.2 to 39.5) | 34.6 (30.0 to 39.3) | 54.6 (42.8 to 64.9) | 41.8 (31.0 to 52.3) |
| Month 24: PD-L1-negative NSCLC analysis set | 22.1 (14.0 to 31.3) | 22.3 (14.7 to 30.9) | 36.0 (18.2 to 54.2) | 17.9 (6.5 to 33.7) |
| Month 24: FAS | 25.7 (21.6 to 30.1) | 23.4 (19.4 to 27.7) | 44.2 (32.9 to 54.8) | 30.4 (20.7 to 40.6) |
Blood samples were collected to determine the serum concentration of durvalumab.
| microgram per milliliter (µg/mL) | Global: Durvalumab + Tremelimumab | China: Durvalumab + Tremelimumab |
|---|---|---|
| Week 0: Pre-infusion | NA ± NA | NA ± NA |
| Week 0: End of infusion | 418.6 ± 74.8 | 392.7 ± 48.9 |
| Week 12: Pre-infusion | 77.5 ± 138.1 | 72.4 ± 55.0 |
| Week 12: End of infusion | 434.3 ± 105.6 | 448.9 ± 40.0 |
| Week 24: Pre-infusion | 108.8 ± 95.7 | 85.6 ± 93.9 |
| Follow-up Month 3 | 8.8 ± 253.9 | 5.4 ± 351.7 |
Blood samples were collected to determine the serum concentration of tremelimumab.
| µg/mL | Global: Durvalumab + Tremelimumab | China: Durvalumab + Tremelimumab |
|---|---|---|
| Week 0: Pre-infusion | NA ± NA | NA ± NA |
| Week 0: End of infusion | 20.3 ± 38.7 | 18.4 ± 43.3 |
| Week 12: Pre-infusion | 3.4 ± 99.6 | 3.3 ± 64.6 |
| Week 12: End of infusion | 20.8 ± 67.4 | 23.2 ± 43.4 |
| Follow-up Month 3 | NA ± NA | NA ± NA |
Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| Participants | Global: Durvalumab + Tremelimumab | China: Durvalumab + Tremelimumab |
|---|---|---|
| ADA positive at any visit (ADA prevalence) | 26 | 1 |
| Treatment-emergent ADA positive (ADA incidence) | 12 | 1 |
| Treatment-boosted ADA | 0 | 0 |
| Treatment-induced ADA (positive post-baseline only) | 12 | 1 |
| ADA positive post-baseline and positive at baseline | 1 | 0 |
| Persistent positive | 11 | 1 |
| Transient positive | 2 | 0 |
| nAb positive at any visit | 3 | 0 |
| ADA positive at baseline and not detected post-baseline | 13 | 0 |
Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.
| Participants | Global: Durvalumab + Tremelimumab | China: Durvalumab + Tremelimumab |
|---|---|---|
| ADA positive at any visit (ADA prevalence) | 49 | 2 |
| Treatment-emergent ADA positive (ADA incidence) | 37 | 1 |
| Treatment-boosted ADA | 1 | 0 |
| Treatment-induced ADA (positive post-baseline only) | 36 | 1 |
| ADA positive post-baseline and positive at baseline | 4 | 1 |
| Persistent positive | 29 | 0 |
| Transient positive | 11 | 2 |
| nAb positive at any visit | 33 | 0 |
| ADA positive at baseline and not detected post-baseline | 9 | 0 |
Collected over Assessed until final analysis DCO for each cohort (24 June 2019 for Global Cohort and 21 September 2020 for China Cohort); maximum timeframe of approximately 44 months for each cohort.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global: Durvalumab + Tremelimumab | 328/410 (80%) | 193/410 (47.1%) | 310/410 (75.6%) |
| Global: SoC Chemotherapy | 329/413 (79.7%) | 112/399 (28.1%) | 349/399 (87.5%) |
| China: Durvalumab + Tremelimumab | 50/78 (64.1%) | 32/77 (41.6%) | 73/77 (94.8%) |
| China: SoC Chemotherapy | 62/82 (75.6%) | 22/78 (28.2%) | 77/78 (98.7%) |
| Event | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 27/410 | 13/399 | 3/77 | 5/78 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/410 | 1/399 | 4/77 | 2/78 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 16/410 | 0/399 | 0/77 | 0/78 |
| PyrexiaGeneral disorders | 12/410 | 1/399 | 3/77 | 0/78 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/410 | 2/399 | 3/77 | 1/78 |
| Bone marrow failureBlood and lymphatic system disorders | 0/410 | 1/399 | 0/77 | 3/78 |
| AnaemiaBlood and lymphatic system disorders | 0/410 | 11/399 | 0/77 | 2/78 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/410 | 0/399 | 2/77 | 0/78 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/410 | 0/399 | 2/77 | 0/78 |
| RashSkin and subcutaneous tissue disorders | 0/410 | 2/399 | 2/77 | 0/78 |
| Event | Global: Durvalumab + Tremelimumab | Global: SoC Chemotherapy | China: Durvalumab + Tremelimumab | China: SoC Chemotherapy |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 59/410 | 146/399 | 25/77 | 53/78 |
| Neutrophil count decreasedInvestigations | 4/410 | 29/399 | 4/77 | 35/78 |
| White blood cell count decreasedInvestigations | 0/410 | 0/399 | 2/77 | 35/78 |
| NauseaGastrointestinal disorders | 57/410 | 128/399 | 10/77 | 33/78 |
| Aspartate aminotransferase increasedInvestigations | 27/410 | 28/399 | 25/77 | 20/78 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/410 | 0/399 | 23/77 | 15/78 |
| Alanine aminotransferase increasedInvestigations | 33/410 | 34/399 | 22/77 | 22/78 |
| Decreased appetiteMetabolism and nutrition disorders | 69/410 | 72/399 | 14/77 | 22/78 |
| Amylase increasedInvestigations | 0/410 | 0/399 | 21/77 | 7/78 |
| Gamma-glutamyltransferase increasedInvestigations | 0/410 | 0/399 | 19/77 | 10/78 |
Global Cohort: The full analysis set (FAS) included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS. China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses. Participants included in both cohorts are not double-counted for the baseline characteristics analysis represented by 'All participants'.
| Age, Customized(Participants) | All Participants: Durvalumab + Tremelimumab | All Participants: SoC Chemotherapy | Total |
|---|---|---|---|
| All participants — <=18 years | 0 | 0 | 0 |
| All participants — Between 18 and 65 years | 278 | 244 | 522 |
| All participants — >=65 years | 196 | 235 | 431 |
| Global cohort — <=18 years | 0 | 0 | 0 |
| Global cohort — Between 18 and 65 years | 233 | 203 | 436 |
| Global cohort — >=65 years | 177 | 210 | 387 |
| China cohort — <=18 years | 0 | 0 | 0 |
| China cohort — Between 18 and 65 years | 53 | 51 | 104 |
| China cohort — >=65 years | 25 | 31 | 56 |
| Sex: Female, Male(Participants) | All Participants: Durvalumab + Tremelimumab | All Participants: SoC Chemotherapy | Total |
|---|---|---|---|
| All participants — Female | 127 | 129 | 256 |
| All participants — Male | 347 | 350 | 697 |
| Global cohort — Female | 113 | 108 | 221 |
| Global cohort — Male | 297 | 305 | 602 |
| China cohort — Female | 18 | 25 | 43 |
| China cohort — Male | 60 | 57 | 117 |
| Race/Ethnicity, Customized(Participants) | All Participants: Durvalumab + Tremelimumab | All Participants: SoC Chemotherapy | Total |
|---|---|---|---|
| All participants — White | 307 | 289 | 596 |
| All participants — Black or African American | 3 | 7 | 10 |
| All participants — Asian | 150 | 165 | 315 |
| All participants — American Indian or Alaska Native | 10 | 12 | 22 |
| All participants — Other | 3 | 4 | 7 |
| All participants — Missing | 1 | 2 | 3 |
| Global cohort — White | 307 | 289 | 596 |
| Global cohort — Black or African American | 3 | 7 | 10 |
| Global cohort — Asian | 86 | 99 | 185 |
| Global cohort — American Indian or Alaska Native | 10 | 12 | 22 |
| Global cohort — Other | 3 | 4 | 7 |
| Global cohort — Missing | 1 | 2 | 3 |
| China cohort — White | 0 | 0 | 0 |
| China cohort — Black or African American | 0 | 0 | 0 |
| China cohort — Asian | 78 | 82 | 160 |
| China cohort — American Indian or Alaska Native | 0 | 0 | 0 |
| China cohort — Other | 0 | 0 | 0 |
| China cohort — Missing | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | All Participants: Durvalumab + Tremelimumab | All Participants: SoC Chemotherapy | Total |
|---|---|---|---|
| All participants — Hispanic or Latino | 50 | 48 | 98 |
| All participants — Not Hispanic or Latino | 423 | 429 | 852 |
| All participants — Missing | 1 | 2 | 3 |
| Global cohort — Hispanic or Latino | 50 | 48 | 98 |
| Global cohort — Not Hispanic or Latino | 359 | 363 | 722 |
| Global cohort — Missing | 1 | 2 | 3 |
| China cohort — Hispanic or Latino | 0 | 0 | 0 |
| China cohort — Not Hispanic or Latino | 78 | 82 | 160 |
| China cohort — Missing | 0 | 0 | 0 |
Showing the first 100 of 210 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2015 to primary completion in Sep 2020, 58 months.
Results were first posted in May 2022, 1 year 8 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 58 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab
Carcinoma, Non-Small-Cell Lung →